The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome

Human Pathology

Volumn 44, Issue 12, 2013, Pages 2768-2773

  Robertson, Scott ^a   Hyder, Omar ^a   Dodson, Rebecca ^a   Nayar, Suresh K ^a   Poling, Justin ^a   Beierl, Katie ^a   Eshleman, James R ^a,b   Lin, Ming Tseh ^a   Pawlik, Timothy M ^a,b   Anders, Robert A ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

BRAF mutations; Intrahepatic cholangiocarcinoma; KRAS mutations

Indexed keywords

ADULT; AGED; ARTICLE; B RAF GENE; BILE DUCT CARCINOMA; CARCINOGENESIS; CLINICAL ARTICLE; FEMALE; GENE FREQUENCY; GENE MUTATION; HUMAN; MALE; ONCOGENE K RAS; OVERALL SURVIVAL; TUMOR GENE; WILD TYPE;

BRAF MUTATIONS; INTRAHEPATIC CHOLANGIOCARCINOMA; KRAS MUTATIONS;

AGED; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SURVIVAL RATE;

EID: 84888018727     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.07.026     Document Type: Article

References (23)

1. G.A. Poultsides, A.X. Zhu, M.A. Choti, and T.M. Pawlik Intrahepatic cholangiocarcinoma Surg Clin North Am 90 2010 817 837
2. K.N. Lazaridis, and G.J. Gores Cholangiocarcinoma Gastroenterology 128 2005 1655 1667
3. T. Patel Worldwide trends in mortality from biliary tract malignancies BMC Cancer 2 2002 10
4. S. Yamamoto, S. Kubo, and S. Hai Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma Cancer Sci 95 2004 592 595
5. B. Glimelius, K. Hoffman, and P.O. Sjödén Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 1996 593 600
6. F.F. Chou, S.M. Sheen-Chen, Y.S. Chen, M.C. Chen, and C.L. Chen Surgical treatment of cholangiocarcinoma Hepatogastroenterology 44 1997 760 765
7. D. Goldenberg, E. Rosenbaum, and P. Argani The V599E BRAF mutation is uncommon in biliary tract cancers Mod Pathol 17 2004 1386 1391
8. A. Tannapfel, F. Sommerer, and M. Benicke Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma Gut 52 2003 706 712
9. A. Tannapfel, M. Benicke, and A. Katalinic Frequency of p16INK4A alterations and k-ras mutations in intrahepatic cholangiocarcinoma of the liver Gut 47 2000 721 727
10. S.A. Ahrendt, A. Rashid, J.T. Chow, C.F. Eisenberger, H.A. Pitt, and D. Sidransky p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer J Hepatobiliary Pancreat Surg 7 2000 426 431
11. S. Furubo, K. Harada, T. Shimonishi, K. Katayanagi, W. Tsui, and Y. Nakanuma Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma Histopathology 35 1999 230 240
12. G.-Y. Gwak, J.-H. Yoon, and C.M. Shin Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas J Cancer Res Clin Oncol 131 2005 649 652
13. D. Sia, Y. Hoshida, and A. Villanueva Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes Gastroenterology 144 2013 829 840
14. J.B. Andersen, B. Spee, and B.R. Blechacz Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors Gastroenterology 142 2012 1021 1031.e15
15. D.R. Borger, K.K. Tanabe, and K.C. Fan Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping Oncologist 17 2012 72 79
16. S. Zingh, S. Chakraborty, N. Bonthu, S. Radio, S.M. Hussain, and A. Sasson Combined hepatocellular cholangiocarcinoma: a case report and review of literature Dig Dis Sci 58 2013 2114 2123
17. E. Massarelli, M. Varella-Garcia, and X. Tang KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin Cancer Res 13 2007 2890 2896
18. A. Lièvre, J.-B. Bachet, and D. Le Corre KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 2006 3992 3995
19. W. Pao, T.Y. Wang, and G.J. Riely KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
20. S. Edge, D. Byrd, A. Compton, and F. Fritz AJCC cancer staging manual 7th ed. 2010 Springer New York, NY
21. A.C. Tsiatis, A. Norris-Kirby, and R.G. Rich Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications J Mol Diagn 12 2010 425 432
22. J.A. Sosman, K.B. Kim, and L. Schuchter Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
23. J.S. Voss, L.M. Holtegaard, and S.E. Kerr Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions Hum Pathol 44 2013 1216 1222